Tumor diversity: Implementing NGS into clinic

Gastric and Breast Cancer

Volumn 11, Issue 3, 2012, Pages 121-126

  Cho, William C S ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EVEROLIMUS; IMATINIB; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; VEMURAFENIB;

BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; CLINICAL FEATURE; COLORECTAL CANCER; DRUG CHOICE; DRUG MECHANISM; GENE MUTATION; GENETIC PROCEDURES; GENETIC VARIABILITY; GENOME ANALYSIS; HIGH THROUGHPUT SEQUENCING; HISTOPATHOLOGY; HUMAN; KIDNEY CANCER; METASTATIC MELANOMA; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; PROGNOSIS; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 84864273026     PISSN: 11097655     EISSN: 11097647     Source Type: Journal    
DOI: 10.2122/gbc.2012.0229     Document Type: Review

References (30)

1. Owens AH, Coffey DS, Baylin SB. Tumor Cell Heterogeneity. Academic Press, New York, 1982.
2. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012 May 16;486(7403):400-4. doi: 10.1038/nature11017.
3. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012 Mar 8; 366(10):883-92.
4. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012 Jan 11; 481(7382):506-10. doi: 10.1038/nature10738.
5. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011 Mar 25;331(6024):1553-8.
6. Roukos DH. "Big" Science: Genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn 2011; 11(2): 123-6.
7. Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg. 2008; 247(4):714-5. (Pubitemid 351440629)
8. Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther. 2006; 6(6): 931-9. (Pubitemid 44201562)
9. Ideker T, Krogan NJ. Differential network biology. Mol Syst Biol. 2012 Jan 17; 8:565. doi: 10.1038/msb.2011.99.
10. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol. 2012;795:1-34.
11. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol. 2012; 8(2):e1002375.
12. Roukos DH. Chromatin: A key player in complex gene regulation and future cancer therapeutics. Epigenomics 2011 Aug; 3(4): 395-9.
13. Camacho DF, Pienta KJ. Disrupting the networks of cancer. Clin Cancer Res. 2012 May 15; 18(10):2801-8.
14. Roukos DH. Spatiotemporal individual genome code-lifestyle network: revolutionizing personal diagnostics. Expert Rev Mol Diagn. 2012 Apr; 12(3):215-8.
15. Roukos DH. Differential signaling transduction networks for clinical robustness. Expert Rev Proteomics. 2012 Apr; 9(2):111-114.
16. Ross-Innes CS, Stark R, Teschendorff AE, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012 Jan 4;481(7381):389-93. doi: 10.1038/nature10730.
17. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: A network-based approach to human disease. Nat Rev Genet. 2011 Jan;12(1):56-68.
18. Roukos DH. Networks medicine: From reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics 2011; 12(5): 695-8.
19. Vogelstein B, Kinzler KW. Winning the war: science parkour. Sci Transl Med. 2012 Mar 28; 4(127):127ed2. doi: 10.1126/scitranslmed.3004019.
20. Roukos DH. Early-stage gastric cancer: A highly treatable disease. Ann Surg Oncol. 2004; 11(2):127-9. (Pubitemid 40486786)
21. Roukos DH, Paraschou P, Lorenz M. Distal gastric cancer and extensive surgery: A new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol. 2000; 7(10): 719-26.
22. Katsios C, Ziogas DE, Roukos DH. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):525-9.
23. Roukos DH, Ziogas DE, Katsios C. Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. Expert Rev Anticancer Ther. 2010 Aug; 10(8):1187-95.
24. Roukos DH. Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices. 2011 Jul; 8(4):409-13.
25. Roukos DH. Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices 2011; 8(2): 123-6.
26. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26; 321(5897):1801-6.
27. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011 Nov 30; 3(111):111ra121.
28. Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature. 2012 Jun 6; 486(7401):80-4. doi: 10.1038/nature11127.
29. Roukos DH. Longevity with systems medicine? Epigenome, genome and environment interactions network. Epigenomics. 2012 Apr; 4(2):119-123.
30. Roukos DH. Biotechnological, genomics and systems-synthetic biology revolution: redesigning genetic code for a pragmatic systems medicine. Expert Rev Med Devices. 2012 Mar; 9(2):97-101.